Program
casdatifan
Also written as “Casdatifan” and “AB521”.
Its studies are mostly in Carcinoma, Renal Cell · Clear-cell metastatic renal cell carcinoma, led by 3 companies.
Drug pageCasdatifan: every studyAll 10 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Arcus Biosciencesits history only | 73 open or running | phase 3since Jun 2, 2025 | Nov 2, 2021 | May 2027phase 1 · NCT07751250 |
| AstraZenecaits history only | 11 open or running | phase 1since May 23, 2025 | May 23, 2025 | Jan 29, 2027phase 1 · NCT07000149 |
| Exelixis | 10 open or running | phase 1since Dec 19, 2023 | Dec 19, 2023 | none ahead |
Also a collaborator on its studies: Summit Therapeutics, LG Chem and Otsuka.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Exelixis only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 19, 2023First study: phase 1 study in Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid TumorsFirst studyNCT06191796 · 25 enrolled · United States
- Aug 11, 2024Named casdatifanINNProposed as its International Nonproprietary Name in WHO's List 131 · before, AB521
TargetBeta
“This is a single-institution, pilot study of oral casdatifan, a selective HIF-2α inhibitor, in patients with metastatic clear cell renal cell carcinoma refractory to prior IO- and VEGF-based therapies.”study text, by rule · the study
Other programs on EPAS1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| belzutifanrule | Merck | phase 3 | 24 |
Studies
The one study Exelixis leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06191796Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors · United States | 1 | Terminated | May 12, 2025 | 25 |
How it is read
Names in the registry
- “Casdatifan”, 6 entries
- “casdatifan”, 2 entries
- “AB521”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Renal Cell, 3 studies
- Clear-cell metastatic renal cell carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.